Bontemps-Gallo Sébastien
Research Associate (CNRS)
ORCID
Contact

 

TRAINING

  • 2021: Habilitation to direct research (H.D.R.) - Univ. of Lille
  • 2013: Ph.D. in Health and Life Science - Univ. of Lille
  • 2010: M.Sc. in Genetics and Microbiology - Univ. of Lille
  • 2008: B.Sc. in Molecular and Cell Biology - Univ. of Lille

POSITIONS HELD

  • Center for Infection and Immunity (CNRS UMR9017, Inserm U1019, U. Lille, Institut Pasteur de Lille)
    • Since 2019: Researcher - civil servant CNRS (CRCN)
    • 2018-2019: Researcher – Pasteur Lille (Sebbane's Lab, Plague and Yersinia pestis)
  • Rocky Mountain Laboratories (NIAID, NIH)
    • 2014-2018: Postdoctoral Visiting Fellow (Gherardini's Lab, Gene Regulation Section)
  • Unité de Glycobiologie Structurale et Fonctionnelle (CNRS UMR8576, U. Lille)
    • 2013-2014: ATER (Lacroix’ Lab)
    • 2010-2013: Ph.D. Student (Lacroix’ Lab)

DISTINCTIONS / RESPONSIBILITIES

  • Member, Steering Committee of the CNRS GDR Bacterial Post-Translational Modifications (since 2023)
  • Elected Member, CoNRS Section 29 (ex: 27 Host–Pathogen Relationships & Immunology), France (2021–2024)
  • Academic Editor for PLoS Pathogens
  • Steering committee member (budget) of the Center for Infection and Immunity of Lille

COMPETENCES / EXPERTISE

Bontemps-Gallo studies how pathogenic bacteria adapt to environmental stresses and how these adaptations shape virulence, with a particular focus on bacterial signaling pathways such as two-component systems. Using a multidisciplinary approach combining genetics, omics, and biochemical methods, his work examines pathogen regulatory mechanisms in situ.

His research addresses three main axes: identifying signaling systems required for host colonization, defining the environmental cues that activate them, and characterizing the downstream effectors that promote survival and invasion. By leveraging multiple host-pathogen models (e.g., Yersinia pestis-flea, Dickeya dadantii-plant, Borrelia burgdorferi-tick), the work aims to uncover conserved adaptive strategies and identify novel therapeutic targets against vector-borne diseases.